PHARMENA SA (PHR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

4Mass SA

PCC Exol SA

PHARMENA SA

Dr. Miele Cosmed Group SA

Why is PHARMENA SA ?

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of -30.55% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 23.51% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of -30.55% over the last 5 years

Flat results in Dec 25

INTEREST(HY) At PLN 0.02 MM has Grown at 260%
ROCE(HY) Lowest at -25.1%
DEBT-EQUITY RATIO (HY) Highest at 0.09 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -7.31%, its profits have fallen by -161.3%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -7.31% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in FMCG)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is PHARMENA SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

PHARMENA SA

-4.55%

-0.85

56.98%

Poland WIG

29.57%

1.74

17.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-30.55%

EBIT Growth (5y)

7.61%

EBIT to Interest (avg)

-3.92

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

0.07

Tax Ratio

31.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

23.51%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.66

EV to EBIT

-10.71

EV to EBITDA

-11.13

EV to Capital Employed

3.73

EV to Sales

22.23

PEG Ratio

Dividend Yield

ROCE (Latest)

-34.82%

ROE (Latest)

-28.70%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

At PLN 0.8 MM has Grown at 625.45%

NET PROFIT(HY)

Higher at PLN -1.58 MM

RAW MATERIAL COST(Y)

Fallen by -13.56% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 0.55 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.24 times

-26What is not working for the Company

INTEREST(HY)

At PLN 0.02 MM has Grown at 260%

ROCE(HY)

Lowest at -25.1%

DEBT-EQUITY RATIO (HY)

Highest at 0.09 %

OPERATING PROFIT(Q)

Lowest at PLN -0.92 MM

PRE-TAX PROFIT(Q)

Lowest at PLN -0.87 MM

NET PROFIT(Q)

Lowest at PLN -0.89 MM

EPS(Q)

Lowest at PLN -0.08

Here's what is working for PHARMENA SA

Net Sales

At PLN 0.8 MM has Grown at 625.45%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (PLN MM)

Inventory Turnover Ratio

Highest at 0.55 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.24 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -13.56% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for PHARMENA SA

Interest

At PLN 0.02 MM has Grown at 260%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (PLN MM)

Net Profit

At PLN -0.89 MM has Fallen at -78.27%

over average net sales of the previous four periods of PLN -0.5 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (PLN MM)

Debt-Equity Ratio

Highest at 0.09 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Profit

Lowest at PLN -0.92 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (PLN MM)

Pre-Tax Profit

Lowest at PLN -0.87 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (PLN MM)

Pre-Tax Profit

At PLN -0.87 MM has Fallen at -40.97%

over average net sales of the previous four periods of PLN -0.62 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (PLN MM)

Net Profit

Lowest at PLN -0.89 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (PLN MM)

EPS

Lowest at PLN -0.08

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (PLN)